APP Pharma to Sell Generic Breast Cancer Drug
SCHAUMBURG, Ill. -- APP Pharmaceuticals Inc. will join Mylan Inc. and Teva Pharmaceutical Industries Ltd. in marketing generic versions of AstraZeneca PLC’s breast cancer drug Arimidex.
APP Pharmaceuticals said Tuesday it will immediately start selling 1-milligram tablets of anastrozole in the United States after the Food and Drug Administration granted marketing approval to Fresenius Kabi Oncology Ltd. Both businesses are units of Germany’s Fresenius Kabi Pharmaceutical Holding Inc.
The drug is used to treat some forms of breast cancer in postmenopausal women. APP Pharmaceuticals said 2009 U.S. sales of Arimidex totaled about $917 million.
Mylan also said Tuesday it received regulatory approval to sell a generic version of Arimidex. On Monday, the FDA approved Teva’s version of the drug.
From Associated Press (June 29, 2010)